美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Aardvark Therapeutics

5.20

-0.5900-10.19%

盤後：5.200.00000.00%16:10 EDT

成交量：82.18萬

成交額：437.28萬

市值：1.13億

市盈率：-2.32

高：5.93

開：5.68

低：5.10

收：5.79

52周最高：17.94

52周最低：4.74

股本：2,169.69萬

流通股本：588.80萬

量比：1.58

換手率：13.96%

股息：- -

股息率：- -

每股收益(TTM):-2.2430

每股收益(LYR):-0.7400

淨資產收益率：-48.06%

總資產收益率：-30.81%

市淨率：0.92

市盈率(LYR):-7.03

資料載入中...

總覽公司新聞資訊公告

BUZZ-券商觀點：Aardvark 暫停後期試驗後下滑；多位分析師下調 PT

美國研究綜述-Aardvark Therapeutics、雪佛龍、Crowdstrike

RBC下調Aardvark Therapeutics評級至行業平配，目標價大幅砍至6美元

BUZZ-Aardvark Therapeutics 暫停晚期罕見病試驗後下跌

Aardvark Therapeutics 暫停罕見病治療後期試驗

Aardvark Therapeutics：因超出目標劑量出現可逆性心臟觀察結果，暫停Hero及開放標籤擴展試驗

Aardvark Therapeutics：基於超目標治療劑量下可逆心臟觀察結果作出決策

Aardvark Therapeutics 成立美國子公司推進皮膚病產品管線發展；任命 Bryan Jones 為首席執行官

Aardvark Therapeutics宣佈向FDA提交併獲IRB批准其主打候選藥物ARD-101的修訂試驗方案，擴大普瑞德-威利綜合徵III期研究受試者資格

BUZZ--美國股票走勢-Invivyd、美國天然氣公司、新紀元能源公司

BUZZ-奧本海默將 Aardvark 評為 "跑贏大盤"，看好其差異化肥胖專營權

Aardvark Therapeutics Inc - 加拿大和英國的臨床試驗地點已獲得註冊許可

Aardvark Therapeutics在澳大利亞進行的英雄三期試驗中宣佈首位患者接受治療

Aardvark Therapeutics宣佈FDA就擴大針對普拉德-威利綜合徵的三期Hero試驗人羣的協議修訂達成一致

美國研究綜述-Carvana、Marvell Technology、Wayfair

美國研究綜述-Carvana、Marvell Technology、Wayfair

LB 製藥公司在美國首次公開募股中籌資 2.85 億美元

生物技術行業陷入困境，LB Pharmaceuticals 着眼於 3.22 億美元的首次公開募股估值

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/AARD/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":5.2,"timestamp":1773259200000,"preClose":5.79,"halted":0,"volume":821772,"hourTrading":{"tag":"盘后","latestPrice":5.2,"preClose":5.2,"latestTime":"16:10 EDT","volume":1737,"amount":9032.4,"timestamp":1773259804765,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.1018998272884283,"floatShares":5888000,"shares":21696893,"eps":-2.243,"marketStatus":"盤後交易","change":-0.59,"latestTime":"03-11 17:39:41 EDT","open":5.68,"high":5.93,"low":5.1,"amount":4372818.637565,"amplitude":0.143351,"askPrice":5.92,"askSize":100,"bidPrice":5.3,"bidSize":20,"shortable":0,"etf":0,"ttmEps":-2.243,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1773273600000},"marketStatusCode":4,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":5.79,"preHourTrading":{"tag":"盘前","latestPrice":5.7,"preClose":5.79,"latestTime":"09:29 EDT","volume":590,"amount":3320.820074,"timestamp":1773235799999,"change":-0.09,"changeRate":-0.015544,"amplitude":0.088083},"postHourTrading":{"tag":"盘后","latestPrice":5.2,"preClose":5.2,"latestTime":"16:10 EDT","volume":1737,"amount":9032.4,"timestamp":1773259804765,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.576256,"impliedVol":0.476,"impliedVolPercentile":0.0294},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","floatShares":5888000,"roa":"-30.81%","roe":"-48.06%","lyrEps":-0.74,"volumeRatio":1.576256,"shares":21696893,"dividePrice":0,"high":5.93,"amplitude":0.143351,"preClose":5.79,"low":5.1,"week52Low":4.74,"pbRate":"0.92","week52High":17.94,"institutionHeld":0,"latestPrice":5.2,"committee":-0.666667,"eps":-2.243,"divideRate":0,"volume":821772,"delay":0,"ttmEps":-2.243,"open":5.68,"prevYearClose":13.125,"prevWeekClose":5.85,"prevMonthClose":12.49,"prevQuarterClose":13.125,"fiveDayClose":5.64,"twentyDayClose":12.61,"sixtyDayClose":15.61},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AARD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"AARD","fiscalQuarterEnding":"2025/09","expectedEps":-0.82,"name":null,"time":"盤後","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.75},{"market":"US","date":"2025-08-13","symbol":"AARD","fiscalQuarterEnding":"2025/06","expectedEps":-0.52,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-05-14","symbol":"AARD","fiscalQuarterEnding":"2025/03","expectedEps":-0.7,"name":null,"time":"盤後","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2025-03-31","symbol":"AARD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AARD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AARD","date":"2026-03-10","current":-2.318324,"percent":0.981132,"low":-51.17654,"twenty":-10.613156,"median":-7.63417,"eighty":-5.785759,"high":-2.187506,"avg":-10.420284,"sd":8.806856,"marketCap":132599226},"quantilePoints":[{"date":"2025-02-21","current":-51.17654,"twenty":-46.993414,"median":-42.216938,"eighty":-39.920668,"marketCap":368880503},{"date":"2025-02-28","current":-39.75453,"twenty":-42.139802,"median":-40.229211,"eighty":-39.232381,"marketCap":286550651},{"date":"2025-03-07","current":-28.243517,"twenty":-40.603022,"median":-39.176012,"eighty":-36.900511,"marketCap":203579269},{"date":"2025-03-14","current":-31.091602,"twenty":-40.336014,"median":-37.766803,"eighty":-30.723725,"marketCap":224108270},{"date":"2025-03-21","current":-27.23482,"twenty":-39.944402,"median":-34.681377,"eighty":-29.198812,"marketCap":196308580},{"date":"2025-03-28","current":-26.404128,"twenty":-39.576524,"median":-30.913597,"eighty":-27.946841,"marketCap":190320955},{"date":"2025-04-04","current":-9.026143,"twenty":-39.119644,"median":-30.068072,"eighty":-27.341623,"marketCap":185830236},{"date":"2025-04-11","current":-7.397773,"twenty":-38.751766,"median":-29.400552,"eighty":-17.252871,"marketCap":152305358},{"date":"2025-04-17","current":-7.977371,"twenty":-38.300819,"median":-28.45119,"eighty":-8.603741,"marketCap":164238114},{"date":"2025-04-25","current":-8.66235,"twenty":-37.766803,"median":-27.946841,"eighty":-8.371497,"marketCap":178340462},{"date":"2025-05-02","current":-11.939711,"twenty":-36.900511,"median":-27.412825,"eighty":-8.371497,"marketCap":245814773},{"date":"2025-05-09","current":-11.307423,"twenty":-34.865316,"median":-26.68597,"eighty":-8.46634,"marketCap":232797221},{"date":"2025-05-16","current":-7.114571,"twenty":-32.693651,"median":-13.552046,"eighty":-8.46634,"marketCap":197215912},{"date":"2025-05-23","current":-7.834638,"twenty":-31.0204,"median":-11.823792,"eighty":-8.360959,"marketCap":217176159},{"date":"2025-05-30","current":-8.061615,"twenty":-30.818661,"median":-11.433881,"eighty":-8.172533,"marketCap":223467976},{"date":"2025-06-06","current":-9.353039,"twenty":-30.367714,"median":-11.107198,"eighty":-8.178795,"marketCap":259266244},{"date":"2025-06-13","current":-8.656453,"twenty":-30.076972,"median":-10.833207,"eighty":-8.210998,"marketCap":239956875},{"date":"2025-06-20","current":-9.454788,"twenty":-30.053238,"median":-10.188135,"eighty":-8.218152,"marketCap":262086713},{"date":"2025-06-27","current":-10.84796,"twenty":-29.697227,"median":-10.664596,"eighty":-8.356744,"marketCap":300705451},{"date":"2025-07-03","current":-10.894921,"twenty":-29.459887,"median":-10.613156,"eighty":-8.365174,"marketCap":302007206},{"date":"2025-07-11","current":-9.861782,"twenty":-29.308323,"median":-10.597502,"eighty":-8.375712,"marketCap":273368592},{"date":"2025-07-18","current":-9.360866,"twenty":-28.618005,"median":-10.433139,"eighty":-8.40036,"marketCap":259483203},{"date":"2025-07-25","current":-10.542714,"twenty":-28.285052,"median":-10.45662,"eighty":-8.474871,"marketCap":292244042},{"date":"2025-08-01","current":-9.4,"twenty":-28.006176,"median":-10.433139,"eighty":-8.577715,"marketCap":260567999},{"date":"2025-08-08","current":-9.368693,"twenty":-27.946841,"median":-10.061366,"eighty":-8.607418,"marketCap":259700162},{"date":"2025-08-15","current":-6.668132,"twenty":-27.567096,"median":-9.861782,"eighty":-8.474871,"marketCap":244307015},{"date":"2025-08-22","current":-5.762071,"twenty":-27.424692,"median":-9.803081,"eighty":-8.329026,"marketCap":211110768},{"date":"2025-08-29","current":-5.027748,"twenty":-27.270421,"median":-9.525229,"eighty":-8.145134,"marketCap":184206621},{"date":"2025-09-05","current":-5.027748,"twenty":-27.074615,"median":-9.478268,"eighty":-8.014507,"marketCap":184206621},{"date":"2025-09-12","current":-4.61321,"twenty":-26.629602,"median":-9.396086,"eighty":-7.797069,"marketCap":169018796},{"date":"2025-09-19","current":-6.685898,"twenty":-23.929853,"median":-9.368693,"eighty":-7.515801,"marketCap":244957921},{"date":"2025-09-26","current":-7.503129,"twenty":-17.043362,"median":-9.298251,"eighty":-7.308831,"marketCap":274899634},{"date":"2025-10-03","current":-9.102059,"twenty":-12.821851,"median":-9.210333,"eighty":-7.389343,"marketCap":333481245},{"date":"2025-10-10","current":-9.824539,"twenty":-12.161077,"median":-9.298251,"eighty":-7.460987,"marketCap":359951454},{"date":"2025-10-17","current":-7.876213,"twenty":-12.040618,"median":-9.212156,"eighty":-7.503145,"marketCap":288568676},{"date":"2025-10-24","current":-6.425331,"twenty":-11.978881,"median":-9.149542,"eighty":-7.334887,"marketCap":235411289},{"date":"2025-10-31","current":-6.194375,"twenty":-11.800608,"median":-9.102059,"eighty":-7.096882,"marketCap":226949500},{"date":"2025-11-07","current":-5.844979,"twenty":-11.619352,"median":-9.083015,"eighty":-6.739195,"marketCap":214148333},{"date":"2025-11-14","current":-6.453893,"twenty":-11.527382,"median":-8.978494,"eighty":-6.599437,"marketCap":236457733},{"date":"2025-11-21","current":-4.209833,"twenty":-11.386619,"median":-8.807467,"eighty":-6.451943,"marketCap":205321954},{"date":"2025-11-28","current":-4.455369,"twenty":-11.26527,"median":-8.719067,"eighty":-6.366112,"marketCap":217297254},{"date":"2025-12-05","current":-5.535729,"twenty":-11.176245,"median":-8.71121,"eighty":-6.20385,"marketCap":269988572},{"date":"2025-12-12","current":-6.968768,"twenty":-11.12541,"median":-8.663092,"eighty":-6.182531,"marketCap":339880775},{"date":"2025-12-19","current":-6.111623,"twenty":-11.06083,"median":-8.610671,"eighty":-6.174808,"marketCap":298076093},{"date":"2025-12-26","current":-6.366088,"twenty":-10.989171,"median":-8.599121,"eighty":-6.172233,"marketCap":310486858},{"date":"2026-01-02","current":-5.859391,"twenty":-10.980741,"median":-8.405995,"eighty":-6.111623,"marketCap":285774195},{"date":"2026-01-09","current":-6.477696,"twenty":-10.894921,"median":-8.362013,"eighty":-6.093766,"marketCap":315930176},{"date":"2026-01-16","current":-6.852697,"twenty":-10.894921,"median":-8.218152,"eighty":-6.111623,"marketCap":334219725},{"date":"2026-01-23","current":-6.732161,"twenty":-10.894921,"median":-8.171191,"eighty":-6.111623,"marketCap":328340941},{"date":"2026-01-30","current":-5.959837,"twenty":-10.857352,"median":-8.086731,"eighty":-6.108052,"marketCap":290673181},{"date":"2026-02-06","current":-5.040192,"twenty":-10.779084,"median":-8.030062,"eighty":-6.020346,"marketCap":245820240},{"date":"2026-02-13","current":-5.482157,"twenty":-10.700911,"median":-7.926792,"eighty":-5.956266,"marketCap":267375780},{"date":"2026-02-20","current":-5.540193,"twenty":-10.673027,"median":-7.864204,"eighty":-5.92323,"marketCap":270206305},{"date":"2026-02-27","current":-5.580372,"twenty":-10.643124,"median":-7.834638,"eighty":-5.890776,"marketCap":272165900},{"date":"2026-03-06","current":-2.562507,"twenty":-10.619417,"median":-7.684115,"eighty":-5.801764,"marketCap":124978581},{"date":"2026-03-10","current":-2.718757,"twenty":-10.613156,"median":-7.63417,"eighty":-5.785759,"marketCap":132599226}],"updateTime":1773263277479},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AARD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2616337005","title":"BUZZ-券商觀點：Aardvark 暫停後期試驗後下滑；多位分析師下調 PT","url":"https://stock-news.laohu8.com/highlight/detail?id=2616337005","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616337005?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 21:33","pubTimestamp":1772458409,"startTime":"0","endTime":"0","summary":"BUZZ-券商观点：Aardvark 暂停后期试验后下滑；多位分析师下调 PT路透3月2日 - ** Aardvark Therapeutics AARD.O周五主动暂停了一项晚期试验，测试其对一种罕见遗传病的实验性治疗，因为在健康志愿者身上发现了与心脏有关的副作用。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nL4S3ZQ1BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2616385122","title":"美國研究綜述-Aardvark Therapeutics、雪佛龍、Crowdstrike","url":"https://stock-news.laohu8.com/highlight/detail?id=2616385122","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616385122?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 15:29","pubTimestamp":1772436594,"startTime":"0","endTime":"0","summary":"美国研究综述-Aardvark Therapeutics、雪佛龙、Crowdstrike路透3月2日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括Aardvark Therapeutics、雪佛龙和Crowdstrike。* Aardvark Therapeutics Inc AARD.O：加拿大皇家银行将其评级从 \"跑赢大盘 \"下调至 \"行业表现\"。* Aardvark Therapeutics Inc AARD.O：加拿大皇家银行将目标价从18美元下调至6美元 * ACM Research Inc ACMR.O：摩根大通将目标价从45美元上调至70美元 * AES Corp AES.N：Seaport Research Partners将其评级从 \"卖出 \"上调至 \"中性\"。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nL4T3ZQ0JE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","MSDL","LU2322448791.USD","IE00BKDWB100.SGD","AVGW","AVGG","IE00BN8TJ469.HKD","BOBS","LU1201861165.SGD","FPS","LU1244550577.SGD","LU2460026573.USD","RRC","AVS","XOMX","LU0949170772.SGD","LU1066053197.SGD","CRWD","AVGX","NMRK","ACMR","BK4129","LU0225283273.USD","LU2756315318.SGD","CRWL","CVX","AVGU","FLUT","MTZ","QSR","LU2211815571.USD","SITC","FSLY","TTDU","AVL","COP","XOMO","XOMZ","LU2462611646.USD","LU2764263203.CNY","LU0466842654.USD","AES","BK4560","SG9999015978.USD","LU1670710588.SGD","LU2065171402.SGD"],"gpt_icon":1},{"id":"1103365650","title":"RBC下調Aardvark Therapeutics評級至行業平配，目標價大幅砍至6美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103365650","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103365650?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 13:52","pubTimestamp":1772430778,"startTime":"0","endTime":"0","summary":"加拿大皇家银行（RBC）宣布，将Aardvark Therapeutics的股票评级从“跑赢大盘”下调至“行业平配”，同时将其目标价从18美元大幅削减至6美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2614602638","title":"BUZZ-Aardvark Therapeutics 暫停晚期罕見病試驗後下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2614602638","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614602638?lang=zh_tw&edition=fundamental","pubTime":"2026-02-28 06:13","pubTimestamp":1772230395,"startTime":"0","endTime":"0","summary":"2月27日 - ** 药物开发商Aardvark Therapeutics AARD.O股价盘后下跌47.2%至6.58美元 ** 该公司表示，它将自愿暂停  其晚期试验，测试其治疗一种罕见遗传病的实验性疗法。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL4S3ZN24Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2614862450","title":"Aardvark Therapeutics 暫停罕見病治療後期試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2614862450","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614862450?lang=zh_tw&edition=fundamental","pubTime":"2026-02-28 05:11","pubTimestamp":1772226675,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics 暂停罕见病治疗后期试验路透2月27日 - Aardvark Therapeutics公司AARD.O周五表示，该公司将自愿暂停其针对一种罕见遗传病的实验性治疗的后期试验。 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL4T3ZN20S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"1162306225","title":"Aardvark Therapeutics：因超出目標劑量出現可逆性心臟觀察結果，暫停Hero及開放標籤擴展試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1162306225","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162306225?lang=zh_tw&edition=fundamental","pubTime":"2026-02-28 05:08","pubTimestamp":1772226491,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics宣布，在发现高于目标剂量出现可逆性心脏相关观察结果后，已决定暂停其Hero试验以及开放标签扩展研究。公司强调，该心脏异常现象在停药后具有可逆性，目前正与监管机构密切沟通，进一步评估相关数据以确定后续研究方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"1177858931","title":"Aardvark Therapeutics：基於超目標治療劑量下可逆心臟觀察結果作出決策","url":"https://stock-news.laohu8.com/highlight/detail?id=1177858931","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177858931?lang=zh_tw&edition=fundamental","pubTime":"2026-02-28 05:08","pubTimestamp":1772226490,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics公司宣布，其决策依据是在高于目标治疗剂量下发现的可逆性心脏观察结果。这一发现对药物安全性评估具有关键意义，表明在特定剂量范围内出现的心脏影响是可逆的，为公司后续临床开发路径提供了重要参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"1174773215","title":"Aardvark Therapeutics 成立美國子公司 推進皮膚病產品管線發展；任命 Bryan Jones 為首席執行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1174773215","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174773215?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 21:06","pubTimestamp":1770901613,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics 宣布成立新的美国子公司，旨在支持其皮肤病产品管线的开发进程。公司同时宣布，任命 Bryan Jones 担任该子公司的首席执行官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"1193243066","title":"Aardvark Therapeutics宣佈向FDA提交併獲IRB批准其主打候選藥物ARD-101的修訂試驗方案，擴大普瑞德-威利綜合徵III期研究受試者資格","url":"https://stock-news.laohu8.com/highlight/detail?id=1193243066","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193243066?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 21:05","pubTimestamp":1770728724,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics今日宣布，已向美国食品药品监督管理局（FDA）提交了其主打候选药物ARD-101的修订临床试验方案，并已获得机构审查委员会（IRB）的批准。此项修订旨在扩大针对普瑞德-威利综合征（PWS）的III期临床研究的受试者资格范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2593473411","title":"BUZZ--美國股票走勢-Invivyd、美國天然氣公司、新紀元能源公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2593473411","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593473411?lang=zh_tw&edition=fundamental","pubTime":"2025-12-24 00:20","pubTimestamp":1766506822,"startTime":"0","endTime":"0","summary":"标普500指数.SPX上涨0.04%，报6881.36点；纳斯达克综合指数.IXIC下跌0.02%，报23425.18点。nL4N3XT0LJ ** Invivyd Inc IVVD.O:BUZZ - 因制药商开始COVID预防抗体的后期试验而上涨。nL4N3XT0M7 ** Freeport-McMoRan Inc FCX.N:BUZZ - 富国银行上调 Freeport-McMoRan PT，因铜业前景光明；股价上涨 nL6N3XT0JK ** Aardvark Therapeutics Inc AARD.O:BUZZ - 奥本海默将 Aardvark 评为 \"跑赢大盘\"，看好其差异化肥胖专营权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL4T3XT0UZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015952.SGD","LU2211815571.USD","IE00B1XK9C88.USD","LU1223083913.SGD","SGXZ81514606.USD","CNX","SOC","BK4139","FSLR","BK4127","IVVD","HIHO","NOW","LU0158827948.USD","HII","RVPH","AZO","NINE","PCLA","AARD","EQT","LU0314106906.USD","SOS","LU2168564495.EUR","EXE","CDE","AFJK","FCX","LU0081259029.USD","NEM","BK4141","IE00B19Z9P08.USD","AME","HL","LU1992135472.HKD","SPRB","LU0654597011.USD","GILD","HXHX","LU2458330169.SGD","LU0154245673.USD","NRDY","LU0094547139.USD","NUAI"],"gpt_icon":1},{"id":"2593349790","title":"BUZZ-奧本海默將 Aardvark 評為 \"跑贏大盤\"，看好其差異化肥胖專營權","url":"https://stock-news.laohu8.com/highlight/detail?id=2593349790","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593349790?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 20:25","pubTimestamp":1766492743,"startTime":"0","endTime":"0","summary":"BUZZ-奥本海默将 Aardvark 评为 \"跑赢大盘\"，看好其差异化肥胖专营权12月23日 - ** 券商奥本海默给予Aardvark Therapeutics AARD.O\"跑赢大盘 \"评级和35美元的目标价，这意味着该股较上一交易日收盘价有超过两倍的上涨空间。** 奥本海默认为，AARD公司即将推出的治疗PWS的实验性药物ARD-101的后期研究结果是一个重要催化剂，并认为与Soleno Therapeutics公司SLNO.O获得FDA批准的药物Vykat XR相比，ARD-101可能具有更好的安全性。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL4T3XT0MU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","SLNO","BK4139"],"gpt_icon":0},{"id":"1119474932","title":"Aardvark Therapeutics Inc - 加拿大和英國的臨床試驗地點已獲得註冊許可","url":"https://stock-news.laohu8.com/highlight/detail?id=1119474932","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119474932?lang=zh_tw&edition=fundamental","pubTime":"2025-12-11 05:24","pubTimestamp":1765401846,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc - 加拿大和英国的临床试验地点已获得注册许可","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"1150804035","title":"Aardvark Therapeutics在澳大利亞進行的英雄三期試驗中宣佈首位患者接受治療","url":"https://stock-news.laohu8.com/highlight/detail?id=1150804035","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150804035?lang=zh_tw&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400713,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics在澳大利亚进行的英雄三期试验中宣布首位患者接受治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"1194886481","title":"Aardvark Therapeutics宣佈FDA就擴大針對普拉德-威利綜合徵的三期Hero試驗人羣的協議修訂達成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1194886481","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194886481?lang=zh_tw&edition=fundamental","pubTime":"2025-10-08 20:02","pubTimestamp":1759924977,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics宣布FDA就扩大针对普拉德-威利综合征的三期Hero试验人群的协议修订达成一致","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2572894145","title":"美國研究綜述-Carvana、Marvell Technology、Wayfair","url":"https://stock-news.laohu8.com/highlight/detail?id=2572894145","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572894145?lang=zh_tw&edition=fundamental","pubTime":"2025-10-01 15:33","pubTimestamp":1759304017,"startTime":"0","endTime":"0","summary":"美国研究综述-Carvana、Marvell Technology、Wayfair路透社10月1日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括 Carvana、Marvell Technology 和 Wayfair。* Marvell Technology Inc MRVL.O：TD Cowen 将其评级从买入下调至持有 * Pool Corp POOL.O：KeyBanc将其评级从行业权重调高至 \"买入\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nL3S3VI0GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRO","SMTC","NAVI","WU","AJG","AXSM","CHYM","BWIN","FOUR","CVNA","BLDR","LW","AXP","AARD","ADSK","MTSI","EEFT","MRVL","ALLY","MMC","HROW","FIS","SYF","SLM","JKHY","ARCB","IPG","ZYME","LU0130102774.USD","POOL","PTGX","BILL","MRCY","ZETA","CPAY","LIF","PAYX","TOST","HHH","MQ","UPWK","OMC","PDM","BFH","BSX","DEI"],"gpt_icon":1},{"id":"2572589411","title":"美國研究綜述-Carvana、Marvell Technology、Wayfair","url":"https://stock-news.laohu8.com/highlight/detail?id=2572589411","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572589411?lang=zh_tw&edition=fundamental","pubTime":"2025-10-01 15:33","pubTimestamp":1759304017,"startTime":"0","endTime":"0","summary":"美国研究综述-Carvana、Marvell Technology、Wayfair路透社10月1日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括 Carvana、Marvell Technology 和 Wayfair。* Marvell Technology Inc MRVL.O：TD Cowen 将其评级从买入下调至持有 * Pool Corp POOL.O：KeyBanc将其评级从行业权重调高至 \"买入\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nL3T3VI0GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPG","LIF","NAVI","MRCY","ALLY","LW","BFH","AXSM","SLM","ZETA","DEI","ADSK","PDM","ARCB","OMC","UPWK","BILL","AARD","BRO","EEFT","MTSI","FIS","POOL","WU","ZYME","MRVL","BWIN","AXP","CPAY","MQ","SYF","AJG","MMC","CVNA","JKHY","FOUR","PAYX","SMTC","HHH","HROW","LU0130102774.USD","PTGX","TOST","BSX","CHYM","BLDR"],"gpt_icon":1},{"id":"2566931627","title":"LB 製藥公司在美國首次公開募股中籌資 2.85 億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2566931627","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566931627?lang=zh_tw&edition=fundamental","pubTime":"2025-09-11 09:18","pubTimestamp":1757553531,"startTime":"0","endTime":"0","summary":"更新版 1-LB 制药公司在美国首次公开募股中筹资 2.85 亿美元从第 2 段起增加详细信息路透社9月11日 - LB Pharmaceuticals 生物技术公司周三表示，该公司在美国首次公开募股中筹集了 2.85 亿美元，这是自 2 月份以来生物技术公司首次大规模公开募股。此次 IPO 对 LB 公司的估值为 3.015 亿美元。该公司股价自2月份上市以来已下跌近一半。该公司计划在 2026 年第一季度开始对急性精神分裂症患者进行为期六周的 LB-102 晚期试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nL3S3UY031:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4127","PIPR","BK4207","MNSH","SF"],"gpt_icon":0},{"id":"2565680373","title":"生物技術行業陷入困境，LB Pharmaceuticals 着眼於 3.22 億美元的首次公開募股估值","url":"https://stock-news.laohu8.com/highlight/detail?id=2565680373","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565680373?lang=zh_tw&edition=fundamental","pubTime":"2025-09-08 22:37","pubTimestamp":1757342235,"startTime":"0","endTime":"0","summary":"生物技术行业陷入困境，LB Pharmaceuticals 着眼于 3.22 亿美元的首次公开募股估值路透社9月8日 - 资金短缺的药物开发商 LB Pharmaceuticals周一表示，其纽约首次公开募股的目标估值将高达 3.216 亿美元，这可能是几个月来美国生物技术公司首次大规模上市。公司背景 LB Pharmaceuticals 公司成立于 2015 年，目前正在开发针对精神分裂症、双相抑郁症和其他神经精神疾病的疗法。下一步计划LB Pharmaceuticals 将在纳斯达克上市，股票代码为 \"LBRX\"。Leerink Partners、Piper Sandler 和 Stifel 是此次发行的主承销商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nL3S3UV13A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","BK4207","PIPR","SF","AARD","MNSH"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}